SELLAS Life Sciences Group logo

SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”SLS” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.sellaslifesciences.com
Founded2012
Disease Focus
Development Stage
STOCK CODENASDAQ: SLS
Address
315 Madison Avenue, 4th Floor, NY, 10017
New York
United States
Email
Contact Number

In Oct. 2014, SELLAS signed a definitive master service agreement with Pharmaceutical Product Development (PPD), to advance and expand clinical and regulatory development across Sellas portfolio of drugs and biologics.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/sellas-life-sciences” connections=”true” suffix=””]

In Dec 2017, SELLAS Life Sciences Group Ltd. merges Galena Biopharma, Inc.; with new company named SELLAS Life Sciences Group, Inc. Earlier, Galenas pipeline consists of multiple mid-to-late-stage clinical assets led by its hematology asset, GALE-401, and its novel cancer immunotherapy programs including NeuVax_ (nelipepimut-S) and GALE-301/GALE-302.

In Sep. 2014, SELLAS signed an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development, marketing, and commercialization of MSKs proprietary WT1 cancer vaccine.

In Apr 2015, SELLAS signed an exclusive global collaboration and license agreement with TrojanTec Ltd, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

In July 2018, SELLAS Life Sciences raised $24.2 Mn through public offering, to commence a pivotal Ph 3 trial of GPS in acute myeloid leukemia, and to develop GPS in combination with pembrolizumab (Keytruda) in a Ph 1/2 proof of concept study